Company profile
CancerNewCo@Memo Therapeutics AG
The technological core of Memo Therapeutics is our droplet microfluidics based single-cell technology platform Dropzylla®. Dropzylla® provides an industry leading sensitivity and versatility in antibody and biologics discovery through its unparalleled efficiency in molecular cloning, expression and functional screening of complete antibody repertoires of human donors or immunized animals. Memo Therapeutics capitalizes on the Dropzylla® platform by developing technologies and candidate therapeutic antibodies for infectious diseases and cancer.
Source: startup.ch
Highlights
Top 100 Swiss Startup Award 2017
Top 100 Swiss Startup Award 2016
Top 100 Swiss Startup Award 2015
The new Swiss Venture Capital Report was published on 26 January. It analyses 304 financing rounds closed in 2020 and includes further article such as an interview with Michael Hengartner, President of the ETH Board, and a list of Swiss "soonicorns". 
